Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Varenicline for smoking cessation in schizophrenia
NCT00702793Phase 4Withdrawn
- Sponsor
- University of British Columbia
- Start
- Apr 2008
- Primary completion
- May 2012
01
Overview
Phase 4, open-label trial of varenicline in nicotine dependence, sponsored by University of British Columbia. Primary endpoints: Positive and Negative Syndrome Scale at 12 weeks and Clinical Global Impression - Improvement at 12 weeks. Planned start Apr 2008; status: withdrawn.
02
Drugs
varenicline
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00702793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00702793.